drugset / Trial / NCT06690164
Study on the Effect of Atorvastatin Co-administered With Omeprazole on Statin Lactone
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a 2-arm, prospective, randomized, parallel-group, open-label, longitudinal study that lasts 30 days for each study participant. This study aims to investigate the effect of co-administration of Omeprazole with Atorvastatin versus Atorvastatin monotherapy on atorvastatin lactone level. Primary endpoint: Higher statin lactone level in intervention arm after 30 days. Secondary endpoints: Higher hs-CRP in intervention arm Lipid panel Incidence of adverse drug side effects (e.g. muscle-related or elevated LFTs
Timeline
- Start
- 2025-06-12
- Primary completion
- 2025-12
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 40 mg | — |
| Subject | Omeprazole | Other / unclassified | 20 mg | — |
Indications
No indication recorded.